Journal article

Spotlight on the utility of the Oncotype DX (R) breast cancer assay

Zhen Rong Siow, Richard H De Boer, Geoffrey J Lindeman, G Bruce Mann

INTERNATIONAL JOURNAL OF WOMENS HEALTH | DOVE MEDICAL PRESS LTD | Published : 2018

Abstract

The Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. It has ushered in the era of genomic-based personalized cancer care for ER-positive primary breast cancer and is now widely utilized in various parts of the world. Together with several other genomic assays, Oncotype DX has been incorporated into clinical practice guidelines on biomarker use to guide treatment decisions. The Oncotype DX result is presented as the recurrence score which is a continuous score that predicts the risk of distant disease recurrence. The assay, which provides informat..

View full abstract